NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 69 filers reported holding NURIX THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,140,117 | -19.0% | 145,053 | +3.0% | 0.00% | – |
| Q2 2023 | $1,407,491 | +124.7% | 140,890 | +99.8% | 0.00% | – |
| Q1 2023 | $626,298 | -21.9% | 70,529 | -3.4% | 0.00% | – |
| Q4 2022 | $801,584 | -17.4% | 73,004 | -2.0% | 0.00% | – |
| Q3 2022 | $971,000 | +44.3% | 74,529 | +40.3% | 0.00% | – |
| Q2 2022 | $673,000 | -94.3% | 53,104 | -93.7% | 0.00% | -100.0% |
| Q1 2022 | $11,802,000 | -64.9% | 842,373 | -27.5% | 0.00% | -60.0% |
| Q4 2021 | $33,649,000 | -8.4% | 1,162,316 | -5.2% | 0.01% | -16.7% |
| Q3 2021 | $36,732,000 | -0.7% | 1,226,058 | -12.1% | 0.01% | 0.0% |
| Q2 2021 | $37,007,000 | -12.5% | 1,394,891 | +2.5% | 0.01% | -14.3% |
| Q1 2021 | $42,296,000 | -47.4% | 1,360,426 | -44.4% | 0.01% | -53.3% |
| Q4 2020 | $80,342,000 | -31.2% | 2,447,584 | -27.3% | 0.02% | -37.5% |
| Q3 2020 | $116,762,000 | – | 3,368,522 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ponoi II Management, LLC | 561,574 | $16,825,000 | 24.93% |
| Ponoi Management, LLC | 561,573 | $16,825,000 | 14.94% |
| TRV GP III, LLC | 2,422,549 | $72,580,000 | 13.78% |
| Foresite Capital Management IV, LLC | 1,205,798 | $36,126,000 | 5.32% |
| Foresite Capital Management V, LLC | 451,522 | $13,528,000 | 4.20% |
| WestHill Financial Advisors, Inc. | 283,333 | $8,489,000 | 2.62% |
| DAFNA Capital Management LLC | 306,320 | $9,177,000 | 2.44% |
| Bain Capital Life Sciences Investors, LLC | 1,284,314 | $38,478,000 | 2.39% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $17,113,000 | 2.02% |
| Redmile Group, LLC | 3,093,077 | $92,669,000 | 1.62% |